Is stereotactic #radiosurgery the standard of care for #breastcancer patients with multiple brain met? Honoured to contribute with Nancy Lin in this Controversy Session chaired by Philip Poortmans Strong emphasis on patient-centred perspectives #ESMOBreast25 ESMO - Eur. Oncology OncoAlert

Results from the VIKTORIA-1 phase 3 trial (2L fulv/palbo/geda vs fulv/geda vs fulv) to be disclosed next Monday morningstar.com/news/globe-new…

🏁latest review from #loilab & our Spanish colleagues #vhio #bcsm OncoAlert TILs Working Group Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer thebreastonline.com/article/S0960-…

Gene expression profiling in a retrospective real-world cohort of #BreastCancer 🧠brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications sciencedirect.com/science/articl… This study investigated the genomic landscape of breast

Results from VIKTORIA-1 just announced by Celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS from 2 to 9.3 months (HR 0.24). Also the fulvestrant/gedatolisib combo improved PFS vs fulv mono (7.4 vs 2 mo, HR 0.33). Quite promising. morningstar.com/news/globe-new…

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 25-31, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Biomarkers🧬of response and resistance to immune checkpoint inhibitors in #BreastCancer by Sherene Loi, MD ✅POETIC

Do gBRCA PVs impact CDK4/6i efficacy in HR+/HER2– MBC? This M-A in The Breast Online included 16,884 pts (618 BRCA) and showed worse PFS & OS with CDK4/6i in BRCA: ➡️ HR for PFS: up to 2.0 ➡️ HR for OS: up to 1.7 Resistance pathways: RB1 loss, ESR1, non-luminal BC. OncoAlert

Link: sciencedirect.com/science/articl… Congrats Michele Bottosso Federica Miglietta Gaia Griguolo #ValentinaGuarneri and all co-authors! 👏

When should we offer risk reducing surgery in women without BRCA1/BRCA2/PALB2 mut? This data can help us better inform this difficult discussion

European Clinical Trial Ecosystem report: 🌍 Global trials ↑ +38% in last 10 yrs 🇪🇺 EU share ↓ from 22% → 12% = ~60,000 fewer trial spots for patients! Reasons? – Fragmented rules – Bureaucracy – Ethics committee delays – Underfunding – Poor tech uptake

Now out in The Lancet the results of the randomized trial ASTER 70s The addition of adjuvant CT to HT had no significant survival benefit in women aged >=70 years with a GGI high-risk ER+ HER2-neg early BC, and had more toxicity 👵🏻🛑 OncoAlert thelancet.com/journals/lance…

🆕article in press: Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis Hope Rugo doi.org/10.1016/j.anno…

Exercise improves outcomes in cancer patients, but HOW?🏋🏼‍♀️ A study in Cell presents a mechanism connecting exercise, microbiota & anti-tumour immunity: exercise induces microbiota to produce formate, which ⬆️ CD8+ T cell functionality OncoAlert cell.com/cell/abstract/…

How is LMD diagnosed? Doctors use 3 tools to diagnose LMD: 1. Neurologic evaluation 2. MRI scans of the brain and spine 3. Lumbar puncture (spinal tap) to test the cerebrospinal fluid (CSF) Let’s walk through each one: #leptomeningeal #brainmets #mdandersonnews #neuronews01

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 8-14, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Extending the duration of ET for early #BreastCancer ✅Nemvaleukin alfa monoTX in advanced #Melanoma

Awarded Basic Science/Pre-Clinical Award at 2025 SNO ASCO #CNSMetastases 🔹In pts with active HER2+ BMs, CSF-ctDNA may better capture tumor genomics & treatment response than plasma-ctDNA — correlative analysis from phase II trial of paxalisib + trastuzumab (NCT03765983)

We are seeing CNS activity with: -multiple ADCs (TDXD, HER3-DXD, TDM1, sacituzumab) -BiTEs (tarlatamab) -bispecifics (ivonescimab) -ICI (ipi/nivo) We need to move to a default of including pts with untreated/progressive brain mets in clinical trials starting in phase 1 !

The last OncoAlert weekly RoundUp is out 👉🏻